Kurzfassung

A 52-week, multicenter, randomized, couble-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis